BCMA-41BB-CD3-IL15 CAR-T cells

BCMA-41BB-CD3-IL15 CAR-T cells are a fourth-generation chimeric antigen receptor (CAR) T-cell therapy designed to target B-cell maturation antigen (BCMA), a protein highly expressed on the surface of malignant plasma cells in multiple myeloma. The construct features a second-generation CAR backbone consisting of an anti-BCMA scFv, a 4-1BB (CD137) costimulatory domain, and a CD3-zeta signaling domain, further armored with the exogenous expression of the cytokine interleukin-15 (IL-15). This design aims to overcome the limitations of standard CAR-T therapies, such as poor persistence and T-cell exhaustion. IL-15 expression promotes a less differentiated memory phenotype (stem cell memory and central memory) and maintains a favorable CD8/CD4 ratio, which are associated with improved clinical outcomes. Developed by researchers at Hospital Israelita Albert Einstein, this therapy has shown robust proliferation, high viability, and enhanced cytotoxicity in preclinical multiple myeloma models without inducing T-cell exhaustion.

Other names

IL-15-armored BCMA CAR-T cellsIL15-armored BCMA CAR-T cellsIL 15-armored BCMA CAR-T cellsBCMA-41BB-CD3-IL15BCMA41BB-CD3-IL15BCMA 41BB-CD3-IL15